Ophthotech in-licenses volociximab for AMD
Ophthotech in-licenses volociximab for AMD
New Jersey-based firm Ophthotech has in-licensed exclusive worldwide rights to the candidate monoclonal antibody drug, volociximab, from fellow US companies Biogen Idec and PDL BioPharma. The deal entitles Ophthotech to develop and commercialize the compound for the treatment of diseases of the back of the eye, including age-related macular degeneration.
Volociximab, which will continue to be developed for solid tumor cancers by Biogen and PDL under their 2005 agreement (Marketletters passim), targets the alpha-5-beta-1 integrin protein, known to be a key factor in angiogenesis. Under its license, Ophthotech will focus on assessing the molecule in AMD, a condition characterized by the aberrant growth of blood vessels.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze